Canada Pension Plan Investment Board Invests $130.89 Million in Regeneron Pharmaceuticals, Inc. $REGN

Canada Pension Plan Investment Board acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the SEC. The fund acquired 209,911 shares of the biopharmaceutical company’s stock, valued at approximately $130,888,000. Canada Pension Plan Investment Board owned 0.20% of Regeneron Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC increased its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Legal & General Group Plc purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $473,872,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on REGN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. HSBC lowered their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Guggenheim upped their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Fifteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $800.36.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals Stock Down 2.3%

REGN opened at $814.79 on Thursday. The business’s fifty day simple moving average is $709.88 and its 200 day simple moving average is $717.69. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $83.89 billion, a PE ratio of 20.14, a P/E/G ratio of 1.42 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $12.81 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 over the last ninety days. Insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.